INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT06429644` - Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations
	Recruiting	`NCT05391763` - Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?	N/A

NCT number	NCT04367675
Study type	Interventional
Source	University of Pennsylvania
Contact	Alex Torres
Phone	855-216-0098
Email	PennCancerTrials@emergingmed.com
Status	Recruiting
Phase	Phase 1
Start date	April 20, 2021
Completion date	December 2025

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms